Novel mechanisms of GPCR functions: AT$_1$ angiotensin receptor acts as a signaling hub and focal point of receptor cross-talk

András D. Tóth$^1$, Gábor Turu$^{1,2}$, László Hunyady$^{1,2,3}$, András Balla$^{1,2}$

$^1$Department of Physiology, Faculty of Medicine, Semmelweis University, Budapest, Hungary, $^2$MTA-SE Laboratory of Molecular Physiology, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary,

$^3$To whom correspondence should be addressed: László Hunyady, Address: Department of Physiology, Faculty of Medicine, Semmelweis University, H-1428 Budapest, P.O. Box 2, Hungary. Tel.: +36 1 266 9180; fax: +36 1 266 6504. E-mail: hunyady.laszlo@med.semmelweis-univ.hu

Abstract

AT$_1$ angiotensin receptor (AT$_1$R), a prototypical G protein-coupled receptor (GPCR), is the main receptor, which mediates the effects of the renin-angiotensin system (RAS). AT$_1$R plays a crucial role in the regulation of blood pressure and salt-water homeostasis, and in the development of pathological conditions, such as hypertension, heart failure, cardiovascular remodeling, renal fibrosis, inflammation, and metabolic disorders. Stimulation of AT$_1$R leads to pleiotropic signal transduction pathways generating arrays of complex cellular responses. Growing amount of evidence shows that AT$_1$R is a versatile GPCR, which has multiple unique faces with distinct conformations and signaling properties providing new opportunities for functionally selective pharmacological targeting of the receptor. Biased ligands of AT$_1$R have been developed to selectively activate the β-arrestin pathway, which may have therapeutic benefits compared to the conventional angiotensin converting enzyme inhibitors and angiotensin receptor blockers. In this review, we provide a summary about the most recent findings and novel aspects of the AT$_1$R function, signaling, regulation, dimerization or oligomerization and its cross-talk with other receptors, including epidermal growth factor (EGF) receptor, adrenergic receptors and CB$_1$ cannabinoid receptor. Better understanding of the mechanisms and structural aspects of AT$_1$R activation and cross-talk can lead to the development of novel type of drugs for the treatment of cardiovascular and other diseases.

Keywords

GPCR, angiotensin II, receptor cross-talk, bias, dimerization.

Abbreviations

α$_2$C-AR, α$_2$C adrenergic receptor; AngII, angiotensin II; AT$_1$R, AT$_1$ angiotensin receptor; β$_2$AR, β$_2$-adrenergic receptor; EGFR, epidermal growth factor receptor; GPCR, G protein-coupled receptors; HB–EGF, heparin-binding epidermal growth factor-like growth factor; RAS, renin–angiotensin system; VSMC, vascular smooth muscle cell
Introduction
The octapeptide (Asp–Arg–Val–Tyr–Ile–His–Pro–Phe) hormone angiotensin II plays a crucial role in the maintenance of blood pressure and fluid homeostasis. It is produced by a two-step cleavage process from the precursor angiotensinogen by protease enzymes, namely renin and angiotensin convertase enzyme (ACE). The AngII effects are mediated by two distinct G protein-coupled receptors (GPCRs), the AT$_1$ and AT$_2$ angiotensin receptors, but there is a substantial difference in their importance in favor of the former. The AT$_1$R is expressed in numerous tissues and mediates the "classical" physiological actions of circulating AngII on mechanisms including blood pressure regulation, salt-water balance, aldosterone secretion and effects on the central nervous system, such as thirst sensation and regulation of sympathetic outflow [1,2]. In addition, increased AT$_1$R activity has been associated with the development of several pathological conditions, including hypertension, heart failure, vascular remodeling, diabetic nephropathy, atherosclerosis and inflammation [2]. Therefore, dampening of AT$_1$R activity has enormous therapeutic benefits and has been successfully exploited in the last decades using ACE inhibitors and AT$_1$R blockers. However, application of these drugs also hinders the beneficial functions of AT$_1$R. In recent years, novel drug compounds with different pharmacodynamic properties were discovered, which are able to selectively activate specific signaling pathways of AT$_1$R. These compounds may reduce side effects and/or have advantageous actions in treatment of diseases and could open a new era in AT$_1$R-targeted therapies.

In addition, a substantial knowledge has been gained about the main properties of AT$_1$R, such as ligand preference, signaling, regulation, and trafficking. However, it is less known how AT$_1$R and other plasma membrane receptors affect each other’s function, and how these crosstalk mechanisms can be utilized in the clinical practice. The new results in the field of receptor crosstalk can reveal not just new drug targets, but can also explain certain interactions between pharmaceutical compounds. In this review, we highlight the traditional and novel features of AT$_1$ angiotensin receptor (AT$_1$R), which is a prototypical GPCR, and can be considered as paradigm for other GPCRs not only in its pleiotropic functions and action of mechanisms but also in its clinical importance and druggability.

Structural aspects of AT$_1$R functions
AT$_1$R is a member of the rhodopsin family of GPCRs, and shares their common structural architecture [1]. It possesses an extracellular N terminus, an intracellular C terminus and seven highly hydrophobic transmembrane α-helices (H1-7), connected by three extra- and intracellular loops (ECL1-3 and ICL1-3, respectively). Ligands of GPCRs can be classified as agonists or antagonists. Agonists are capable to induce structural rearrangements in the receptor, achieving an active conformation of the GPCR, whereas antagonists stabilize the inactive state. Our understanding of the structural aspects of GPCR activation has improved strikingly in recent years thanks to the growing numbers of high-resolution GPCR structures. Surprisingly, despite the relatively low sequence homology between GPCRs, the conformational features of the transmembrane helices are considerably conserved [3]. In contrast, the composition of ligand binding pockets is diverse among GPCRs, which ensures the specific recognition of receptor ligands. Accordingly, our knowledge of the interaction between AT$_1$R and its specific antagonists (or more precisely: inverse agonists) has hugely improved by the first crystal structures of AT$_1$R in complex with the AT$_1$R antagonists ZD7155 and olmesartan [4,5]. In good agreement with the previous results of site-directed mutagenesis studies, the ligand binding pocket of AT$_1$R is formed by several key residues of ECL2 and the transmembrane helices H1, H2, H3 and H7. With the help of docking
Simulations, these structures could explain the different binding properties of various receptor blockers. For instance, losartan, an antagonist with a relatively low binding affinity, forms only one salt bridge with the ligand binding pocket, whereas candesartan, an antagonist with insurmountable binding, is speculated to engage AT$_1$R with two additional salt bridges [4]. The knowledge of the antagonist-stabilized state may also help to predict the conformational changes of the agonist-stimulated AT$_1$R.

**Signal transducers of AT$_1$R**

Heterotrimeric G proteins initiate the first wave of GPCR signaling (Fig. 1) [6]. Upon agonist activation, the Ga subunit binds to the core region of active GPCRs via the opened cytosolic cavity. This interaction triggers nucleotide exchange of Ga from GDP to GTP and dissociation of Ga from Gβγ. The separated subunits modulate the activity of downstream effector proteins to induce robust signaling cascades. These signaling mechanisms have wide spectra, including second messenger generation, activation of small G proteins and cytoplasmic tyrosine kinases, regulation of ion channels or transactivation of growth factor receptors. Likewise, G protein-mediated signaling pathways are responsible for the vast majority of AT$_1$R-evoked cellular responses [1]. AngII stimulation of AT$_1$R is able to activate not just one but various G proteins, such as G$_q$/11, G$_i/o$, or G$_{12/13}$ [7]. G$_{q/11}$ protein induces the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP$_2$) into the second messenger inositol trisphosphate (IP$_3$) and diacylglycerol (DAG) by activation of phospholipase Cβ, IP$_3$ triggers intracellular Ca$^{2+}$ mobilization via binding and opening its calcium channel receptor. Ca$^{2+}$ is a central regulator of many intracellular proteins and, in cooperation with DAG, also leads to the activation of various protein kinase C (PKC) isoforms [1,2]. Meanwhile, the signal transduction via G$_{i/o}$ and G$_{12/13}$ proteins lead to inhibition of adenylyl cyclase, regulation of L- and T-type Ca$^{2+}$ channels and activation of phospholipase D, Rho GTPases or Rho kinase. It seems that the G$_{q/11}$-mediated signal transduction mechanisms of AT$_1$R prevail in the major physiological target tissues, including kidney, adrenal cortex, vascular smooth muscle and cardiac cells [2].

The first wave of signaling is terminated by the elimination of the GTP bound to Ga and by distinct mechanisms of desensitization [8]. In the course of homologous desensitization, GRK enzymes recognize and phosphorylate agonist-bound GPCRs on serine/threonine residues of the receptor C-tail and/or ICL loops. The phosphorylation contributes to receptor desensitization through promotion of high affinity binding of arrestin proteins [9]. Moreover, since GRKs have a large number of non-receptor targets, they may also act as effectors of GPCR signaling [10]. Although the phosphorylation target sites of the seven GRK isoforms show substantial overlap, there are marked differences as well. It was demonstrated that distinct ligands of the β$_2$AR initiate different phosphorylation patterns in the cytoplasmic tail of the receptor, “barcode”, due to alternative interaction with GRK2 and/or GRK6 [11]. Similarly, different phosphorylation barcode by GRK2/3 and GRK5/6 were suggested in the case of AT$_1$R [12,13]. In addition, the C-tail of AT$_1$R contains several consensus PKC phosphorylation sites [14]. Phosphorylation by PKC can be induced by activation other plasma membrane receptors and occurs not only in the active but the inactive state of the receptor. This mechanism of regulation of AT$_1$R sensitivity is termed as heterologous desensitization.

GRK-phosphorylation of agonist-bound AT$_1$R is followed by the recruitment of β-arrestins. β-arrestins are multi-functional adaptor proteins of GPCRs. The two β-arrestins (β-arrestin1 and β-arrestin2) are expressed ubiquitously in mammalian tissues, and show high sequence and structural homology [9]. Their major roles are identical, but several isoform-specific functions were also reported (reviewed in [15]). They bind receptors in a two-step process [16]. First, β-arrestins interact with receptor-attached phosphates, then dock to the
intrahelical cavity of the activated GPCR. The binding of β-arrestin to the GPCR core sterically prevents the further activation of G proteins. Moreover, activated β-arrestins can interact with numerous adaptor proteins involved in the endocytic cargo transport [8]. Association of β-arrestin with the β2-appendage of adaptor protein 2 induces translocation of the GPCR-β-arrestin complex to clathrin-coated pits, which step is followed by internalization mediated by clathrin-coated vesicles. AT1R interacts with β-arrestins in sustained manner, due to strong interaction of β-arrestins with phosphorylated C-terminal serine/threonine clusters [17,18]. Because of the stable interaction, AT1R and β-arrestins internalize together as a complex. This allows β-arrestins to govern the intracellular trafficking of the receptor [8]. Basically, receptors can have two fates after endocytosis (Fig. 2). They can be degraded in lysosomes or be recycled to the plasma membrane via fast and/or slow recycling endosomes. During recycling, the receptor ligands detach from the receptor due to lower pH in endosomes, and the receptor is dephosphorylated by protein phosphatases. These processes induce resensitization of the receptor, i.e. they are able to respond to agonists again. Sustained β-arrestin binding of AT1R favors late endosomal and lysosomal trafficking, inducing its down-regulation [8]. Furthermore, β-arrestin-independent and caveolae-mediated internalization routes of AT1R have also been described [19].

Initially, β-arrestins were considered only as negative regulators of GPCR functions by mediating receptor desensitization and internalization. It is now widely-accepted that they have much broader roles, as they are central organizers of distinct signaling cascades [16]. As scaffolds, they orchestrate a vast array of signaling proteins, such as various mitogen-activated protein kinases (MAPK), phosphoinositide 3-kinase, Akt or protein phosphatase 2A [16,20,21]. In that function, β-arrestins fine tune a second wave of GPCR signaling. This signaling is substantially different from the first wave regarding its temporal, spatial and mechanistic features [6]. One of the most known β-arrestin-mediated function is the modulation of MAPK activation. Various MAPK cascade members are regulated by β-arrestins upon AT1R activation, including Raf1, MEK, ERK, p38 MAPK and JNK [16]. The formation of AT1R–β-arrestin–MAPK complexes alter the localization of MAPK activation. These complexes keep activated MAPKs away from the nucleus, thereby preventing the induction of their transcriptional response [20]. On the other hand, the β-arrestin-bound MAPK complexes can phosphorylate and regulate other target proteins, which are brought in proximity as well by β-arrestins. β-arrestins were shown to interact with hundreds of signaling proteins, indicating that β-arrestins are central regulators of complex signaling networks [22,23]. Among a wide range of functions, β-arrestins regulate cytoskeletal rearrangements, chemotaxis, or protein synthesis. In the light of these observations, it is not surprising that β-arrestins were demonstrated to mediate a plethora of AT1R effects, such as positive inotropy in the heart, cardiac hypertrophy or proliferation of cardiomyocytes [24–26].

Interestingly, β-arrestins show a remarkable degree of conformational plasticity [9]. They can adopt multiple active conformations with distinct signaling properties. An important determinant of the β-arrestin conformation is the receptor C-terminal phosphorylation barcode [16]. Different phosphorylation motifs induce distinct β-arrestin conformational changes, which provides the possibility to evoke distinct AT1R induced cellular responses [12]. In addition, activated β-arrestins are ubiquitinated by ubiquitin ligases, such as Mdm2 [27]. Interestingly, the ubiquitination patterns of β-arrestin may differ in the distinct active conformations, which may contribute to the fine regulation of β-arrestin-mediated response [27].

Recent data suggest that the β-arrestin-mediated second signaling wave is dependent on G proteins, suggesting that β-arrestins, in fact, broaden the signaling options of G proteins by governing their signaling in time and space [28]. Interestingly, several GPCRs have been reported to generate a third, sustained signaling wave from endosomes after internalization.
Interestingly, GPCR–G protein–β-arrestin supercomplexes have been identified to be responsible for the sustained endosomal signaling [31]. In contrast to the generally believed competition between G proteins and β-arrestins, in this complex Ga binds to the receptor core and β-arrestin interacts with the phosphorylated C-tail of the same receptor. These results were obtained with G, protein-coupled GPCRs, and it would be curious to investigate whether the mainly G, coupled AT1R could form such complexes as well. These data shed light on the complex interplay between the GPCR transducers and suggest that spatiotemporal features of signaling are more prominent than they were previously supposed.

In addition to the above-mentioned effectors, GPCRs also have numerous other interacting partners. These proteins can be either plasma membrane proteins such as ion channels, transporters, various serine/threonine-specific protein kinases, cytoskeletal proteins, Src homology and PDZ domain-containing proteins, small G proteins or extracellularly located adhesion molecules [32]. Accordingly, AT1R was shown to interact with wide spectra of other proteins beside G proteins and β-arrestins, such as AT1R-associated protein (ATRAP), phospholipase Cγ, JAK2 or other GPCRs, just to name a few, which may also take important parts in the complex pleiotropic effects of AT1R in the target tissues of the renin-angiotensin system (RAS) [1].

### Biased agonism of AT1R

β-arrestin binding and internalization of AT1R and other GPCRs does not require G protein activation [28,33–35]. Although recent data suggest that β-arrestin-mediated signaling of GPCRs requires G protein activation [28], β-arrestin binding and its effect on receptor regulation is G protein independent, therefore compounds that selectively activate G proteins and β-arrestin binding (biased or functional selective compounds) can modify the intracellular fate of receptors, which may have therapeutic relevance. It was speculated that AT1R may adopt multiple active conformations with distinct signaling properties, and conformation-specific targeting of AT1R could offer the intriguing possibility of pathway-selective intervention. Evidence for this concept is the successful development of β-arrestin-biased peptide agonists [36]. These peptides induced no or partial activation of G proteins, while they triggered efficient receptor phosphorylation and β-arrestin recruitment (Fig. 3A-B) [7,35]. Using AT1R conformational biosensors, it was demonstrated that the conformations stabilized by β-arrestin-biased peptides are indeed distinct from that of the AngII-induced conformation [37]. These biased peptides lack the aromatic amino acid in position 8, the indispensable residue for adoption of the G protein-activating conformation of AT1R. The first such a peptide was [Sar1, Ile4, Ile8]-AngII, which was then followed by a series of higher-affinity ligands including, TRV120023 or TRV120027 [38]. These peptides revolutionized AT1R pharmacology and unveiled new aspects of AT1R functions [39]. In addition, they show not only selective activation of the β-arrestin-mediated signaling pathway but change the intracellular trafficking of AT1R [40,41]. The altered intracellular fate upon treatment with β-arrestin-biased compounds may be explained by the interesting finding that they also induce a different active conformation of the β-arrestin [42,43]. In addition, lack of G, dependent hydrolysis of PIP2, a known determinant of endocytosis [44], accelerates internalization of the receptor, which may have profound effects on the spatiotemporal features of signaling (Fig. 2) [40,45]. Moreover, these results offer the intriguing possibility that biased agonists could be applied in diseases where the intracellular receptor processing should be changed. The unique pharmacodynamic properties of biased agonists were also demonstrated in vivo, as they possessed beneficial effects on cardiac contractility and performance [38,46]. Unfortunately, although promising results were obtained with TRV120027 for the treatment of acute heart failure in animal studies [39,47], it failed to deliver the expected results in a Phase II clinical trial [48]. However, long-term treatment with another β-arrestin-biased peptide, TRV120067
was shown to have benefits compared to losartan treatment in a mouse model of dilated cardiomyopathy [49]. This suggests that chronic treatment with biased agonists could still be useful in the therapeutic strategies of some cardiovascular diseases. Although β-arrestin-mediated signaling pathways were mostly suggested to be beneficial, β-arrestin activation could also have adverse side effects. In the treatment of certain conditions, such as aldosterone overproduction, the preferable medicines will still probably be the full antagonists of AT1R, such as candesartan or valsartan, since the use of β-arrestin-biased compounds may lead to aldosterone escape [50], due to the fact that the aldosterone production is partly β-arrestin mediated in response to AngII [51].

**AT1R as a stretch mechano-sensor**

There is a growing number of evidence that AT1R not only behaves as a hormone receptor, but also serves as a sensor of membrane stretch [52–55]. In that function, AT1R is activated in the absence of ligand binding and shows biased signaling properties. Upon osmotic stretch, AT1R binds β-arrestin in a Gαi/o activity dependent manner, but does not activate Gq/11 proteins [55]. These processes are followed by the transactivation of epidermal growth factor receptor (EGFR) and activation of ERK [55]. This mechanism was suggested to mediate the Frank-Starling law of the heart, i.e. the enhanced contraction response upon increased ventricular filling [56].

**AT1R as a signaling hub**

It was generally believed that the signal transduction of AT1R requires ligand binding and/or adoption of its active conformation. As reviewed above, activated AT1R induces a plethora of signaling pathways, in contrast to inactive AT1R, which was thought to be silent in terms of signaling. It has been demonstrated that pharmacological activation of PKC causes β-arrestin2 recruitment to AT1R even in the absence of receptor agonists [57]. Moreover, stimulation of either epidermal growth factor receptor or a distinct Gq/11-coupled GPCR, such as α1A-adrenergic receptor or endogenous purinergic receptors could exert the same effect, proving that the interaction can be triggered at physiological levels of PKC activation (Fig. 3C). It was also found that this heterologous mechanism of β-arrestin recruitment to AT1R was not sensitive to treatment with the inverse agonist candesartan, showing that this process does not require the active state of the receptor. However, it depends on stable association between the PKC-phosphorylated serine/threonine clusters in the receptor’s C-terminus and two conserved phosphate-binding lysines of β-arrestin2. Using β-arrestin2 conformational biosensors it was demonstrated that β-arrestin2 binds to PKC-phosphorylated AT1R in a distinct conformation. Moreover, this conformation is also active functionally, since it triggers MAPK recruitment and receptor internalization with altered intracellular receptor trafficking. Taken together, the unliganded, but phosphorylated AT1R is able to recruit β-arrestins and consequently, the inactive AT1R may also participate in signaling as a scaffold protein [57]. This mechanism could be particularly important in the cases of receptors, like α1A-adrenergic receptor, which do not interact with β-arrestins, since the presence of AT1R could aid them to initiate β-arrestin dependent signaling. Since phosphorylation of AT1R is induced by a variety of other receptors, the β-arrestin activation by heterologously-phosphorylated AT1R may represent a central cross-talk mechanism for regulation of signal transduction.

**Transactivation mechanisms driven by AT1R**

**Cannabinoid receptor regulation by AT1R**

Cannabinoid receptors (CB1 and CB2 receptors) were first recognized as the targets of the phytocannabinoid tetrahydrocannabinol, the active compound of marijuana [58,59]. Later
on, anandamide and 2-arachidonoyl glycerol (2-AG) were described as the main endocannabinoids produced in brain and other tissues [60]. The role of 2-AG as a cannabinoid receptor ligand was an intriguing finding, since it is produced from DAG by DAG lipase (DAGL) [61]. Since DAG is produced after G Proteins activation, and DAGL is expressed widely in many tissues, we have hypothesized that AT₁R stimulation may lead to production of 2-AG. Indeed, 2-AG is produced in cell culture models after stimulation of the AT₁R with AngII, leading to activation of the CB₁ cannabinoid receptor (CB₁R) in both autocrine and paracrine manner (Fig. 3E) [62,63]. Moreover, it has been shown later, that in different arteries [64–67] and central nervous system AT₁R function is altered by CB₁R activation, which effects are dependent on DAGL activity [68]. AngII itself induces contraction in rat and mouse aorta and coronary, renal, skeletal, muscle and pulmonary arteries, and this effect is attenuated through the parallel induction of 2-AG production and activation of CB₁R [64–67]. This mechanism may serve as a fine-tuning negative feedback regulation in the vasomotor system, dampening the effects of many Gq-coupled receptors in vascular smooth muscle cells (VSMCs), which may serve as a protection mechanism from overactivation. Although the interaction between the RAS and the cannabinoid system seems to be present in the arteries, identification of the precise cellular location of the individual elements requires additional studies.

AT₁R–CB₁R interaction is not limited to the regulation of endocannabinoid release. In rat astrocytes, AngII-induced PKC-mediated phosphorylation and heterologous desensitization of the cannabinoid receptors [69]. In these cells, CB₁R activity inhibits the MAP kinase pathway, and desensitization may regulate the balance between active and inactive receptors after activation through endocannabinoid release. Alternatively, CB₁R receptor signaling bias might be regulated through PKC-mediated phosphorylation, although these aspects of the interaction have not been yet investigated. On the other hand, AT₁R–CB₁R heterodimerization has also been reported in Neuro2A cells, where AT₁R-induced full ERK1/2 required expression of the CB₁R [70]. Together, these data show that there may be multiple levels of interaction between RAS and the cannabinoid system, which may be distinct in different tissues and cell types. They also suggest that autocrine and paracrine activations of CB₁R might be not just spatially, but also functionally different.

**EGFR transactivation by AT₁R**

It is very characteristic for the AT₁R that several cellular responses upon AngII stimulation are mediated by receptor tyrosine kinases, among which the EGFR plays the most important role in the cardiovascular system [71] and in other tissues, such as hepatocytes [72]. The EGFR transactivation is mediated via calcium signal and matrix metalloprotease (ADAM) activation, which causes the cleavage of heparin-binding epidermal growth factor-like growth factor (HB–EGF) resulting in agonist release for the EGFR stimulation (Fig. 3E) [73]. It turned out that this mechanism is crucial for several pathological effects of AngII, including cardiac and vascular remodeling, and the pharmacological inhibition of ADAM17 can be promising new possibility in treatment of hypertension [74]. Although EGFR transactivation seems to be the most important among growth factor receptor transactivation pathways, other growth factor receptors including insulin-like growth factor I receptor, and platelet-derived growth factor receptor transactivation mechanisms in physiological target cells, such as VSMCs, were demonstrated in response to AngII stimulation [75].

**Dimer formation of AT₁R with other GPCRs**

It is now widely accepted that AT₁R is capable to form higher order complexes, i.e homodimers/oligomers and heterodimers/oligomers with other GPCRs. Several GPCR–AT₁R heterodimers were published, including adiponectin receptor [76], α2C-adrenergic receptor
(α2C AR) [77], apelin receptor [78], β2AR [79], bradykinin B2 receptor [80], CB1 cannabinoid receptor [70], chemokine (C-C Motif) receptor 2 [81], prostaglandin F2α receptor [82] and purinergic P2Y6 receptor [83]. Interestingly, several dimers have been associated with altered ability to activate G protein and/or β-arrestins (Fig. 3D). For instance, several studies have demonstrated that homodimerization has negative allosteric effect on AT1R function [84–86], and recently the structural requirements of homodimer formation were proposed [87]. In addition, heterodimerization between the mainly Gs-coupled α2C AR and Gi-coupled AT1R was shown to change their G protein preference, and switches to Gs proteins and cAMP signaling [77]. Furthermore, altered pharmacological profile of the heterodimerized AT1R and β2AR has been demonstrated. Antagonist binding of either receptor was found to induce trans-inhibition of the other protomer, i.e. one antagonist could block the G protein activation of both receptors [79]. The AT1R–β2AR heterodimer also influences the β-arrestin binding properties [88]. Dual agonist occupancy potentiates the β2AR–β-arrestin recruitment without affecting the β-arrestin binding of AT1R. β-arrestin biased AT1R agonists, in contrast to the conventional AT1R antagonists, could also evoke this phenomenon [88]. These results suggest that some pharmacological effects of β-arrestin-biased AT1R agonists may be transmitted by the regulation of β2AR leading to unexpected side effects of these drugs. However, it must be noted that physical interaction between receptor dimer partners, was mostly demonstrated using methods prone to inherent errors, and several parallel independent experimental approaches, as well as careful experimental design [89] is needed to verify many of these findings.

**AT1R in diseases**

The overactivity of AT1R is detrimental, induces pathophysiological conditions, and frequently associated with various diseases especially in the cardiovascular system and in the kidney. Due to the complexity of the AT1R signaling, the various cell/tissue/organ dysfunctions could be promoted by several parallel mechanisms. The growth factor transactivation (mainly EGFR) is accounted as the key player in AngII-induced maleficent cardiac and vascular hyperplasia and hypertrophy [90]. In addition, excessive AngII-induced reactive oxygen species (ROS) production can lead to oxidative stress within the cells by promoting lipid, protein, and nucleic acid oxidations. Depending on the type of cells the oxidative stress itself can result in endothelial dysfunction, cardiovascular remodeling, hypertension, cardiac and vascular smooth muscle cell hypertrophy, diabetes, atherosclerosis [91]. AngII also induces inflammatory signals [92], and the proinflammatory actions of AT1R were implicated in the development of several diseases including hypertension, myocardial and renal fibrosis [93,94]. On top of the cardiovascular and renal symptoms, the deleterious AngII signaling is also implicated in metabolic diseases and diabetes based on the results of clinical studies using various AT1R blockers [95,96]. The mechanisms which lead to those conditions are not fully understood, although it is well established that insulin resistance can be caused by excessive AngII action and the blockade of RAS improves the insulin sensitivity [97].

**Concluding remarks**

In recent years, the high-resolution crystal structures of antagonist-bound AT1R greatly improved our understanding of the molecular aspects of AT1R functions. However, there is still an urgent need for the structures of both unbiased and biased agonist-bound AT1R, which could aid the development of biased compounds with better pharmacodynamic profile. Although TRV120027 failed in a trial of acute heart failure, investigation of biased drugs in other diseases is highly desirable to answer whether these compounds be could be applied in
clinical practice. The new insights of receptor cross-talk mechanisms showed that AT\textsubscript{1}R is much more complex than previously appreciated. Further studies are needed to answer whether the cross-talk mechanisms of AT\textsubscript{1}R could be successfully targeted in the treatment of diseases.

**Practice points:**
- Recent results of biased agonism help to understand how different drugs acting on the same GPCR can have different pharmacological effects.
- The wide array of therapeutic effects of ACE inhibitors and AT\textsubscript{1}R blockers, including blood pressure control, renoprotection, amelioration of peripheral inflammation, and beneficial effects in metabolic disorders, are mediated not only by dampening RAS activity but most likely also by hindering the endocannabinoid and growth factor receptor tyrosine kinase pathways.
- Drug interactions can be caused by receptor cross-talk mechanisms.
- Exploitations of receptor interactions and biased agonism offer the possibility of new therapeutic strategies in the near future

**Research agenda:**
- Determination of high-resolution structures of unbiased and biased agonist-bound AT\textsubscript{1}R
- Elucidation of the spatiotemporal properties of AT\textsubscript{1}R actions and the role of internalized receptors in G protein activation and signaling
- Development of novel biased AT\textsubscript{1}R agonists with better pharmacokinetic and dynamic profiles
- Investigation of the effects of biased compounds in different disease models
Conflict of interest
The authors declare that there is no conflict of interest.

Acknowledgements
This work was supported by the Hungarian National Research, Development and Innovation Fund (NKFI K116954, and NVKP_16-1-2016-0039), and the ÚNKP-17-3-III-SE-23 New National Excellence Program of the Ministry of Human Capacities (ADT).

References:


[84] Hansen JL, Theilade J, Haunso S, Sheikh SP. Oligomerization of wild type and nonfunctional mutant angiotensin II type I receptors inhibits galphaq protein signaling


The activation of a GPCR usually initiates multiple and complex signaling pathways in the target cells. The first wave of signaling depends on the G protein coupling and second messenger production. The β-arrestin binding not just decouple the receptor from G protein but serving as a signaling scaffold initiates the slightly delayed second, β-arrestin-mediated wave of receptor signaling. Recent evidences revealed that the internalized receptors are also capable to organize a third wave of signaling, which results in sustained cell response.
Figure 2. Intracellular trafficking of AT$_1$R

Agonist stimulation of AT$_1$R leads to endocytosis predominantly via a β-arrestin- and dynamin-dependent mechanism. The internalized receptors can either be degraded through the late endosomal/lysosomal route or be resensitized and recycled to the cell surface by recycling endosomes. The β-arrestin-biased AT$_1$R peptides promote distinct and accelerated trafficking of the receptor due to the lack of PIP$_2$ depletion in the plasma membrane and the different β-arrestin binding properties.
Figure 3. Pleiotropic functions of AT1R signaling

AT1R acts as multifaceted organizer of signal transduction processes. (A) AT1R can interact with various effector proteins, including Gq/11, Gi/o, G12/13 proteins and β-arrestin molecules. (B) Binding of ligands with different pharmacodynamic properties or membrane stretch can promote distinct conformational rearrangements in the receptor, leading to alternative signaling outcomes: blockade or activation of distinct downstream effectors. (C) The inactive AT1R acts as a focal point of signaling of other plasma membrane receptors via β-arrestin recruitment. (D) AT1R can function in distinct molecular compositions. Homodimerization of AT1R induces allosteric trans-inhibition in the dimer partners, whereas the heterodimerization with other receptors can alter the G protein preference and/or the β-arrestin binding properties. (E) Transactivation mechanisms driven by AT1R. In many cell types, AT1R acts also via transactivation of other receptors, including growth factor receptor transactivation (i.e. EGFR) and GPCR transactivation (i.e. CB1R).